Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade ...

Holzkirchen, March 6, 2015-Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio(TM) (filgrastim-sndz) for all indications included in the ...

Novartis’ (NVS) generic arm, Sandoz, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of its biosimilar version of ...

- Nivestim(TM), Hospira's filgrastim, has received approval from the European Commission (EC) for the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced ...

Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings. Objectives: ...

A biosimilar version of filgrastim (EP2006, Sandoz/Novartis) has today been recommended for approval in the United States. The new product is like a generic version of the brand-name filgrastim, ...

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...

Novartis International AG / Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely ...

Holzkirchen, March 6, 2015- Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio (filgrastim-sndz) for all indications included in the reference ...

Pfizer Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM ™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible ...